Autism Spectrum Disorder (ASD) Mental and Behavioural Disorders Pervasive developmental disorders
Conditions
Interventions
L-carnitine supplied in a liquid preparation by the Wellness Pharmacy (Birmingham, AL, USA) using a specific formula containing: 100 mg L-Carntine/mL with the inactive ingredients of methylcellulose,
Sponsors
Autism Research Institute (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects diagnosed with an ASD 2. Aged from 3 to 10 yrs-old (males and females) 3. Study subject bodyweights between 13.2 Kg to 40.4 Kg
Exclusion criteria
Exclusion criteria: 1. No study subject previously received carnitine-based therapy or previous methionine or lysine supplementation 2. No study subject had any change in therapy or treatment (including medications) within 1 month prior to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Childhood Autism Rating Scale (CARS) Study participants will be evaluated using a CARS test conducted only by a single study investigator who observed the subjects and interviewed the parent(s), and was unaware as to the treatment status of the subject. The CARS test is a 15-item behavioural rating scale developed to identify autism as well as to quantitatively describe the severity of the disorder. The CARS test is a well-established measure of autism severity. The internal consistency reliability alpha coefficient is 0.94; the inter-rater reliability correlation coefficient is 0.71; and the test-retest correlation coefficient is 0.88. CARS scores have high criterion-related validity when compared to clinical ratings during the same diagnostic sessions, with a significant correlation of 0.84. 2. Autism Treatment Evaluation Checklist (ATEC) Each study subject will be evaluated by their parents using an ATEC form. Parents will be unaware as to the treatment status of their child. The ATEC, designed by the Autism Research Institute (San Diego, CA, USA), is a one-page form. It consists of four subtests designed to measure the effects of treatment in persons with autism. The items are: (1) Speech/Language/Communication (14 items); (2) Sociability (20 items); (3) Sensory/Cognitive Awareness (18 items); and (4) Health/Physical/Behavior (25 items). The internal consistency reliability of the measure is high (0.94 for the Total score). The ATEC has been successfully used to measure treatment effects in autism. 3. Clinical Global Impression (CGI) An overall CGI score will be collected by a single study investigator unaware of the treatment status of the study subject using a 3 point scoring system defined as follows: subject improved = 1, subject the same = 2, and subject worse = 3. 4. Hand Muscle Testing Each subject will have their hand muscle strength tested using a pneumatic, adjustable squeeze pinch-gauge/dynamometer (Baseline Evaluation Instruments; White Plains, NY | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Treatment Adherence Measure (TAM) Form A treatment adherence measure (TAM) form will be completed by the parents of each study subject. Parents will be unaware as to the treatment status of their child. The TAM is a ten-item self-report on treatment adherence that asks specific questions regarding the dose and frequency of use. The TAM was used to calculate the level of adherence to the treatment. It is a Morisky-type self-report adherence measure, designed to measure treatment adherence. Morisky-type adherence measures have been used widely, demonstrating good reliability as a self-report measure. 2. Side effects 2.1. Frequency and Intensity of Side Effect Rating (FISER) 2.2. Global Rating of Side Effect Burden (GRSEB) 2.3. Patient Report of Incidence of Side Effects (PRISE) The FISER/GRSEB/PRISE forms will be completed by the parents of study subjects that will be unaware of the treatment status of their children. The FISER/GRSEB/PRISE forms include global measures, each using a 7-point Likert-type scale rated 0-6, with one rating anchored for frequency, another rating the intensity of side effects encountered in the prior week that the study subject parents believed were due to the treatment, and the third asking the parents of study subjects to estimate the overall burden or degree of interference in day-to-day activities and function due to the side effects attributable specifically to the treatment. Frequency of side effects is rated as a percent time present: 0 = no side effects; 1 = present 10% of the time; 2 = 25% of the time; 3 = 50% of the time; 4 = 75%; 5 = 90%; and 6 = present all of the time. Intensity of side effects ranges from 0 = no side effects to 6 = intolerable side-effects. Impairment due to side effects ranges from 0 = no side effects to 6 = unable to function at all due to side-effects. The PRISE lists a variety of possible side effects from which to choose and a scale to rate the specific side effect. The measure also has a place to list | — |
Countries
United States of America
Outcome results
None listed